A Research Guide for
Parkinson's Disease Dementia

A neuropsychological evaluation for suspected PDD assesses multiple cognitive domains. The profile of which domains are impaired (and which are relatively preserved) helps confirm the diagnosis and guides care planning. The domains tested include:

• Attention and concentration: The ability to focus on a task and sustain that focus. Impaired attention is one of the earliest and most prominent features of PDD — more severe than in Alzheimer's disease at a comparable cognitive stage
• Executive function: Planning, organizing, sequencing, and solving novel problems. Early executive dysfunction in PDD affects complex activities of daily living (managing finances, following multi-step recipes, scheduling) while basic self-care is still intact
• Visuospatial abilities: Judging spatial relationships, copying geometric figures, interpreting what is seen. PDD causes prominent visuospatial impairment early, which distinguishes it from Alzheimer's disease (where language and memory are more affected early)
• Memory: In PDD, verbal memory is impaired but often less severely than in Alzheimer's disease. Importantly, people with PDD tend to benefit more from cues and prompts (e.g., being given the first letter of a word they can't retrieve), while people with Alzheimer's disease often cannot use cues effectively even if given them
• Language: Generally relatively preserved in early-to-moderate PDD compared to Alzheimer's disease, though word-finding difficulties (anomia) may occur
• Processing speed: The speed of thinking and responding. Slowed processing is universal in PDD and often more severe than in other dementias

Cognitive test scores are most useful when tracked over time. A single score tells you where someone is now; the change in scores between visits (typically 6 or 12 months apart) tells you about the rate of progression. Neurologists and neuropsychologists use these scores to:

• Confirm the diagnosis and stage of dementia (mild, moderate, or severe)
• Assess whether cognitive medications (rivastigmine, memantine) are having benefit or whether the dose should be adjusted
• Determine when driving is no longer safe
• Identify when certain tasks (managing finances, managing medications independently) need to be transferred to a caregiver
• Support legal planning conversations about when cognitive capacity may be affected

Interpreting the numbers: For the MoCA (0–30 scale), the typical thresholds used clinically are: 26–30 = normal; 18–25 = mild cognitive impairment or mild dementia; 10–17 = moderate dementia; <10 = severe dementia. These are approximate guides, not rigid cutoffs. A score in the mild range with preserved daily function has very different implications than the same score in someone who can no longer manage medications independently.

Performance variability: Because cognitive fluctuations are characteristic of PDD, a person may perform somewhat differently on tests done on different days. A single testing session captures a snapshot; the neuropsychologist will note whether the results seemed consistent with the history being reported at home.

• Which cognitive domains were most affected in the testing?
• How does this profile fit with PDD versus other causes of dementia?
• What is the expected rate of change? Should we retest in 6 months or 12 months?
• At what score level does driving become unsafe, in your clinical judgment, given this patient's other symptoms?
• Are there specific activities where the level of impairment means supervision is now needed?
• When should we involve a neuropsychologist for a full evaluation rather than just bedside screening?

Levodopa (usually given as carbidopa-levodopa/Sinemet) is the most effective treatment for Parkinson's motor symptoms. In PDD, that goal has to be balanced against the cognitive effects of dopamine stimulation. Some PDD patients find that higher levodopa doses worsen hallucinations, confusion, or impulsive behavior — this is called dopaminergic psychosis. However, under-treating the motor symptoms leads to rigidity, freezing, falls, and reduced mobility.

Practical points about levodopa in PDD:

• Timing matters: Levodopa works best when taken 30–60 minutes before meals or 1–2 hours after meals, because protein in food competes with levodopa for absorption. Consistent timing improves motor predictability
• Protein redistribution diet: Some people benefit from eating most of their daily protein at the evening meal, keeping daytime meals lower in protein to maximize levodopa absorption during active hours
• "On" and "off" states: As PDD and Parkinson's progress, the effect of each levodopa dose becomes shorter and less predictable. Your neurologist can add a long-acting formulation or other Parkinson's medications to smooth out these fluctuations
• Do not stop levodopa suddenly without neurologist guidance. Abrupt discontinuation can cause a severe withdrawal-like syndrome with fever, rigidity, and serious complications

Several drug classes require special caution or should be avoided in PDD because of the risk of severe motor worsening, cognitive worsening, or life-threatening reactions:

• Traditional antipsychotics (AVOID): Haloperidol, olanzapine, risperidone, and similar dopamine-blocking antipsychotics can cause severe and sometimes irreversible worsening of Parkinson's motor symptoms in people with Lewy body pathology. This neuroleptic sensitivity reaction can be life-threatening. A medical ID bracelet indicating "Lewy body / PDD — avoid antipsychotics" is strongly recommended
• Anticholinergic medications (CAUTION): Diphenhydramine (Benadryl), trihexyphenidyl, benztropine, oxybutynin, and many other medications with anticholinergic properties can significantly worsen memory and cognition in PDD. Avoid unless specifically prescribed by the neurologist who knows the full medication list
• Sedating medications (CAUTION): Benzodiazepines (lorazepam, diazepam, clonazepam), sleep aids (zolpidem/Ambien), and sedating antihistamines can cause excessive sedation, increased fall risk, and worsening confusion. Use only as specifically directed by the neurologist
• Dopamine-blocking antiemetics (AVOID without neurology input): Metoclopramide (Reglan), prochlorperazine (Compazine), and promethazine block dopamine and can severely worsen Parkinson's motor symptoms. For nausea in PDD, ondansetron (Zofran) is generally preferred

• Use a pill organizer or automated dispenser. Missing a Parkinson's medication dose because the person forgot they already took it (or forgot to take it) is a significant risk as PDD progresses. Pre-filled weekly pill organizers, or automated pill dispensers with timed alarms, reduce errors significantly
• Track who is giving medications. In households with multiple caregivers or family members, it is easy to accidentally double-dose. Assign one person to manage medications, or use a log that notes each dose given
• Rivastigmine patch rotation: The rivastigmine patch should be applied to a different skin site each day. Keep a simple rotation chart. Apply the patch at the same time each day. Remove the old patch before applying a new one — failure to remove the previous patch risks double-dosing, causing severe nausea
• Bring a complete medication list to every appointment — including over-the-counter medications, vitamins, and supplements. Drug interactions are common in PDD, and any prescriber outside the neurology team should be aware of the full list before adding new medications

Regular physical exercise is the single intervention with the most consistent evidence for slowing functional decline in Parkinson’s disease, and emerging evidence supports this in PDD specifically. Exercise affects multiple PDD biology targets simultaneously: it increases brain-derived neurotrophic factor (BDNF, a growth factor that supports neuron health), improves cerebral blood flow, reduces neuroinflammation, and improves sleep quality. Practically, it also reduces fall risk by maintaining muscle strength and balance.

What type of exercise?

• LSVT BIG: A physical therapy program specifically developed for Parkinson’s disease that uses high-amplitude, large-movement exercises to counteract the characteristic small, shuffling movements of PD. Shown to improve motor function and gait speed. Sessions are conducted by a certified LSVT BIG physical therapist, typically 16 sessions over 4 weeks, followed by home practice.
• Aerobic exercise: Walking, cycling, swimming, or treadmill at moderate intensity (able to hold a short conversation) for 30 minutes at least 3 times per week. Produces both motor and cognitive benefits. Safety: always with supervision or at minimum a well-fitted walking aid for people with moderate PDD given fall risk.
• Balance and strength training: Tai chi, standing balance exercises, resistance band training. Reduces fall frequency — arguably the most important outcome in moderate PDD. Referral to a physical therapist familiar with Parkinson’s disease for a home exercise program design is strongly recommended.
• Dance: Tango and other partnered dance programs have been studied specifically in Parkinson’s disease with consistent motor and social benefit findings. Dance Rock Steady (rockysteadyboxing.org has a directory of PD-adapted programs) and Dancing With Parkinson’s are community programs in many cities.

Safety note: Exercise in PDD must be carefully supervised, especially for people with moderate impairment. Contact the PDD neurologist before starting a new exercise program to identify any cardiac or orthopedic contraindications and discuss medication timing (ideally exercise during the motor "on" period).

Cognitive stimulation therapy (CST) — structured group or individual sessions that engage the person in thinking, reminiscence, and social interaction — has strong RCT evidence in Alzheimer’s disease and is being increasingly applied in PDD and DLB. Even without a formal CST program, the principle applies: regular mentally engaging activity is associated with slower cognitive decline.

Practical ways to provide cognitive stimulation in PDD:

• Reading aloud together (even reading to someone who cannot read independently anymore provides stimulation)
• Reminiscence activities: looking at family photo albums, listening to music from the person’s young adulthood, watching old films from their youth
• Simple puzzles adapted to current ability (crosswords adapted, picture puzzles, word-search books)
• Gardening (raised-bed gardening is accessible for people with limited mobility)
• Cooking simple familiar recipes with assistance — familiar procedural memory often remains intact longer than declarative memory
• Artwork, music, or craft-based activities with family members or in adult day programs

Important: match the activity difficulty to the person’s current cognitive level. Activities that are too difficult cause frustration and withdrawal; those calibrated to the person’s current ability produce enjoyment, engagement, and a sense of accomplishment. A good occupational therapist can assess the person and recommend appropriate activities.

A common misunderstanding is that palliative care means "giving up." In fact, palliative care can be provided alongside any treatment, at any stage. It is not the same as hospice, which is specifically for people who are no longer pursuing curative treatment and have a life expectancy of 6 months or less. Palliative care in PDD includes:

• Expert symptom management for pain, sleep disturbance, depression, anxiety, and challenging behavioral symptoms
• Clarifying what matters most to the person with PDD and their family — their values, goals, and preferences for care
• Helping families navigate difficult decisions about hospitalizations, surgery, feeding tubes, and resuscitation
• Reducing unnecessary tests and treatments that add burden without adding quality to life
• Supporting the family and caregiver (including their grief and mental health)
• Coordinating care across the many providers involved in PDD

Palliative care teams typically include physicians, nurses, social workers, and chaplains, and are distinct from the neurology team. Referral to palliative care in PDD is appropriate when:

• Symptom burden is high and the neurology and primary care teams feel additional expertise would help
• The family is having difficulty with goals of care discussions or advance care planning
• Caregiver distress is severe
• The person is entering the moderate-to-severe stage of PDD

Hospice is appropriate when the focus of care shifts entirely to comfort, quality of life, and time with loved ones, and when a physician certifies that if the disease follows its expected course, life expectancy is six months or less. In PDD, signs that hospice may be approaching include:

• Inability to walk even with assistance (complete motor dependence)
• Complete dependence for all activities of daily living including eating and hygiene
• Inability to recognize family members or speak meaningfully
• Recurrent aspiration pneumonia despite modified diet and positioning
• Significant weight loss (>10% in 6 months) despite nutritional support
• Inability to swallow safely, with the family having declined a feeding tube after informed discussion

Hospice in PDD is typically provided at home (the most common setting) or in a nursing facility. Families often report that their biggest regret is not calling hospice sooner. Hospice teams bring expertise in pain management, secretion control (to reduce the distressing "death rattle" from retained secretions), anxiety treatment, and family support that most families cannot access on their own.

In Utah, contact the Utah Hospice and Palliative Care Organization (utahhospice.org) for a directory of hospice providers. Most hospice services are covered in full by Medicare Part A for patients who qualify.

The main investigational directions for PDD as of 2024–2025 include:

• Alpha-synuclein targeting: Agents designed to reduce, neutralize, or clear the abnormal alpha-synuclein that forms Lewy bodies are the most prominent direction in Parkinson's-related research. Results in Parkinson's disease trials have been mixed to date; PDD-specific alpha-synuclein trials are ongoing. This is the most promising mechanistic direction but is still in early-to-mid clinical development.
• Cholinergic system enhancement: Beyond the existing ChEIs (rivastigmine, donepezil), researchers are exploring more targeted cholinergic approaches, including nicotinic receptor agonists and other mechanisms that specifically address the cholinergic deficit in PDD (which is more severe than in Alzheimer's disease).
• GBA enzyme replacement and chaperone therapy: For the subset of PDD patients with GBA gene variants, therapies designed to restore glucocerebrosidase enzyme activity may slow the disease process specifically in GBA-PDD. Ambroxol (a mucolytic drug repurposed as a GBA chaperone) is in trials for GBA-Parkinson's disease and PDD. Venglustat and other substrate reduction therapies have been tested in clinical trials.
• Sigma-1 receptor agonists: Blarcamesine (ANAVEX2-73) targets the sigma-1 receptor, which is involved in cellular stress responses and autophagy. Investigated in DLB and PDD; results from a Phase 2a trial showed modest cognitive signals warranting further study.
• Neuroprotective strategies: Exercise (particularly aerobic and forced exercise approaches) is being investigated not only for symptomatic benefit but potentially for disease-modifying effects through neuroplasticity mechanisms. The SPARX3 and similar trials are evaluating high-intensity treadmill exercise in early Parkinson's disease.
• Sleep and RBD intervention: Research is examining whether treating REM sleep behavior disorder (before dementia develops) can modify or delay the onset of Lewy body dementia. Clonazepam and melatonin intervention studies in isolated RBD are ongoing.

The primary resource for finding PDD and DLB clinical trials in the United States is ClinicalTrials.gov. Searching for "Parkinson's disease dementia" or "Lewy body dementia" with filters for "Not yet recruiting" or "Recruiting" status will show currently enrolling trials. The Fox Trial Finder at michaeljfox.org is a curated, patient-friendly tool that matches people with Parkinson's disease (including PDD) to relevant trials based on location and characteristics.

What to ask when contacting a trial:

• What are the eligibility criteria? (Key exclusions often include severe dementia, certain medication combinations, or cardiac conditions)
• How many visits are required and at what locations?
• Are travel expenses or caregiver time reimbursed?
• What are the risks of the experimental treatment? What is the placebo rate?
• What happens if the trial ends early?
• Can I continue my current medications during the trial?

Inform your neurologist before joining any clinical trial — trial medications may interact with current Parkinson's drugs, and some trials have medication eligibility requirements. Your neurologist can help evaluate whether a specific trial is appropriate for your situation.

People with PDD generally function better with a predictable, structured daily routine. Unpredictable changes cause more confusion and distress than familiar activities, even repetitive ones. Building a consistent daily structure helps the person with PDD anticipate what comes next, reduces agitation, and makes caregiving more sustainable.

Effective morning routine principles:

• Rise at the same time each day — consistent sleep-wake timing helps regulate the sleep-wake cycle and may improve nighttime sleep quality
• Take Parkinson's medications first thing in the morning (before breakfast if possible) to allow the levodopa to take effect during the most active part of the morning routine. The "morning off" period before medications kick in is one of the most dangerous times for falls
• Structure morning activities from easiest to most cognitively demanding — basic self-care (teeth, face, dressing) while cognition is still warming up, more cognitively demanding activities (reading, conversation, decision-making) later in the morning after the levodopa has taken full effect
• Build in enough time — rushing increases anxiety and fall risk. If a task took 20 minutes last year, it may take 45 minutes now. Factor this into the schedule rather than trying to maintain previous timeframes
• Keep mornings calm and low-stimulation — loud TV, complex conversation, or multiple concurrent demands during the morning transition are common sources of confusion and agitation in PDD

Scheduling activities by cognitive state: Many families learn to identify the 2–4 hour window when the person with PDD is most cognitively alert and physically mobile (usually mid-morning, 1–2 hours after morning medications). Scheduling the most important activities — medical appointments, meaningful social interactions, bathing, exercise — during this window maximizes success and minimizes distress.

Maintaining as much independence as possible in activities of daily living (ADLs) preserves dignity and reduces caregiver burden. The goal is not to do things for the person with PDD, but to set up the environment and tasks so they can do as much as possible themselves safely. Occupational therapy (OT) is the specialty that focuses specifically on this, and an OT home visit is one of the highest-value referrals in early-to-moderate PDD.

Dressing:

• Replace buttons and zippers with Velcro closures, magnetic snaps, or elastic waistbands
• Lay clothes out in the order they will be put on the night before
• Sit to dress whenever possible — reduces fall risk dramatically
• Slip-on shoes or elastic laces eliminate the hazard of untied laces while maintaining independence

Bathing:

• Walk-in showers with a shower seat and handheld showerhead are dramatically safer than tub baths in PDD. If a tub conversion is not possible, a bath transfer bench allows safe tub bathing without needing to step over the high tub wall
• Non-slip mats inside and outside the shower are essential
• A grab bar at the entry point of the shower and a second bar inside are minimum safety additions
• As motor function declines, scheduling bathing during the medication "on" state improves safety significantly

Eating and kitchen safety:

• Adapted utensils (weighted utensils for tremor, built-up handle grips, angled spoons) improve eating independence and reduce meal-time stress
• A plate guard or lipped plate prevents food from sliding off
• Cups with weighted bases or sippy-style cups reduce spills
• As swallowing becomes problematic, consult a speech-language pathologist for food texture recommendations before a choking episode or aspiration event occurs
• Remove stove access once cooking safely is no longer possible — this is one of the most common home hazard concerns in moderate PDD

The home environment should be modified proactively, before falls occur, because the consequences of falls in PDD are severe (hip fractures, head injuries, hospitalization-related delirium).

High-priority modifications:

• Remove trip hazards: Loose rugs, extension cords crossing walkways, low furniture in pathways, thresholds between rooms, and clutter. This is the single most impactful fall prevention modification
• Bathroom safety: Grab bars beside the toilet and in the shower (not towel bars, which are not load-bearing — grab bars must be anchored to studs). A raised toilet seat with armrests makes sitting and rising from the toilet much safer
• Adequate lighting: Night lights in hallways, bathroom, and bedroom. Automated motion-sensing lights eliminate the need to fumble for switches during nighttime bathroom trips. The person with PDD should never navigate a dark hallway
• Stair safety: Both stair handrails solid and anchored; stair lighting adequate; consider a stair gate at the top of stairs for overnight safety if nighttime confusion is present. Single-story living is strongly preferred in moderate-to-advanced PDD
• Bed height: The bed should be at a height where the person's feet are flat on the floor when sitting on the edge of the bed, to allow safe rising. Bed rails should be partially raised (not full-length) to assist with turning, with padding on any hard edges
• Personal emergency response system (PERS): A wearable button that calls for help if the person falls. Most important for periods when the person is alone at home. Many systems now include fall detection (automatic alert without pressing the button). Medicare Advantage and many Medicaid plans cover PERS; basic monthly costs range from $20–$50/month

Prepare the environment first:

• Turn off the television or radio before starting a meaningful conversation — background noise is significantly more disruptive in PDD than for cognitively intact people
• Make eye contact and come to their level (sit if they are sitting) before beginning to speak
• Use their name to signal that you are speaking to them specifically
• Time conversations during the cognitive "on" period — roughly 1–2 hours after morning Parkinson's medications

How to phrase things:

• Short, simple sentences. One idea per sentence. Long compound sentences with multiple clauses lose people with PDD mid-sentence.
• Ask yes/no questions rather than open-ended questions when a decision needs to be made. "Would you like tea?" works much better than "What would you like to drink?" as PDD progresses
• Offer two choices at most for decisions that need input: "Would you like the blue sweater or the red one?" rather than presenting the whole closet
• Avoid "Do you remember...?" This question format highlights memory failure and creates shame. Instead, share the memory as a statement: "I was thinking about when we went to Lake Powell together."
• Don't finish sentences or correct errors unless the error creates a safety issue. People with PDD need time to process and respond. The natural conversational pause is often 3–5 seconds longer in PDD than usual. Wait.
• When they can't find a word, offer options: "Is it something you drink? Something in the kitchen?" rather than either guessing immediately or leaving them struggling alone

Managing Parkinson's voice problems: Hypophonia (very soft voice) makes it difficult to understand what the person is saying. Strategies include: asking the person to speak louder explicitly ("Can you say that again, a little louder?"); reducing ambient noise; speech therapy (LSVT LOUD) to improve voice volume; and family members learning to listen more carefully rather than asking the person to repeat multiple times (which causes frustration and discouragement from attempting conversation).

As verbal communication becomes very difficult in advanced PDD, families often underestimate how much connection is still possible through non-verbal means. Research consistently shows that people with advanced dementia can still:

• Respond to and convey emotion through touch, facial expression, tone of voice, and body language
• Recognize and respond emotionally to music from earlier in their life, even when they can no longer identify the song or recall the memory
• Respond to familiar smells (a partner's perfume, a favorite food) when verbal recognition is absent
• Experience comfort and distress, even when they cannot report it verbally

Simple communication techniques that remain effective in advanced PDD:

• Hold their hand during difficult care routines — familiar touch is calming even when words are not understood
• Play music they loved at age 20–30 (the "reminiscence bump" — music from young adulthood retains emotional power longest in dementia)
• Speak in a calm, slow, warm voice even when they appear unresponsive — hearing and emotional processing are often preserved even when response ability is absent
• Photo books and familiar objects from earlier in life can spark recognition and connection when abstract verbal conversation cannot

There is no single cognitive score or symptom threshold that defines when driving becomes unsafe — driving fitness is a clinical assessment that considers multiple factors. The following are established red flags that strongly suggest driving should be evaluated or stopped:

• MoCA score below 24 (mild dementia range) in combination with Parkinson's motor symptoms substantially increases crash risk. Some guidelines suggest formal driving evaluation for any person with PDD regardless of score
• Visual hallucinations that intrude during wakefulness — visual disturbances while driving are an immediate safety concern regardless of insight level
• Significant motor fluctuations with unpredictable "off" episodes (sudden onset of stiffness, tremor, or freezing) while driving
• Any at-fault accident or near-miss in the preceding 12 months
• Getting lost in familiar areas, difficulty finding the way home from places driven to routinely
• Excessive daytime sleepiness or documented episodes of falling asleep unexpectedly (which can occur with Parkinson's medications, especially dopamine agonists)
• Family or passenger concern about driving safety — family-reported concern has strong predictive validity for actual driving impairment in dementia

Involve the neurologist: Asking the neurologist to raise the driving question (rather than a family member being the "bad guy") often lands better. Many states, including Utah, require or permit physicians to report patients with medical conditions that impair driving ability to the DMV. In Utah, the Driver License Division can receive physician reports and may require a driving evaluation or impose restrictions.

Formal driving evaluation: A certified driving rehabilitation specialist (CDRS) — often an occupational therapist with specialized training — can provide an objective driving evaluation, including both in-office cognitive testing and an on-road driving test. This removes subjectivity from the family dynamic. Recommendations from a CDRS (continue, continue with restrictions, or stop) carry more weight with the person with PDD than family opinion. Find a CDRS through the Association for Driver Rehabilitation Specialists (ADED) at driver-ed.org.

If driving must stop: Transportation alternatives should be identified before driving stops, not after. Options include: family or friend transportation networks (scheduling this in advance is critical); medical transport services (arranged through the PDD person's insurer or Medicaid for medical appointments); ride-share apps (Lyft and Uber have programs for older adults, and some family members manage the app for their relative); community volunteer driver programs; and paratransit services through local transit agencies for people with disabilities.

Driving cessation dramatically increases social isolation and depression risk in older adults, particularly men for whom driving is strongly tied to independence and identity. Planning for this transition is not just a safety matter — it is a wellbeing matter.

• Frame driving cessation as a transfer of responsibility ("I need to be your driver now") rather than a loss of privilege
• Create a reliable weekly schedule of outings that maintain the person's connection to activities they value
• For people who loved to drive as an activity, consider passenger rides specifically for the pleasure of the outing, not just for errands
• Watch for worsening depression after driving cessation — this is a high-risk period and should be assessed by the clinical team
• Consider involving the person in planning their transportation so they retain some sense of control and agency

Burnout does not arrive suddenly; it builds over months. Recognizing the early warning signs allows intervention before a crisis occurs. Warning signs include:

• Exhaustion that is not relieved by rest — waking up tired even after sleeping
• Feeling isolated — withdrawing from friends, family, and activities you used to enjoy
• Feeling hopeless — believing that no matter what you do, nothing will improve
• Neglecting your own health — skipping your own doctor appointments, medications, meals, or exercise
• Increased irritability, resentment, or anger toward the person you are caring for (followed by guilt)
• Physical symptoms: headaches, stomach problems, frequent illness (stress suppresses immune function)
• Depression or anxiety symptoms that persist for more than two weeks

If you recognize these warning signs in yourself, treating them is not selfish — it is necessary to sustain the care you provide. Caregiver burnout is the most common reason for premature nursing home placement; addressing it directly keeps more people at home longer.

Build in respite systematically: Respite — planned breaks from caregiving — must be a regular, scheduled part of the care plan, not something that only happens in a crisis. Options include adult day programs (typically 4–8 hours, 2–5 days per week); in-home respite care (a trained aide comes to the home to allow the primary caregiver to leave); overnight respite at a memory care facility; family/friend-based respite rotations; and VA caregiver respite programs for veterans and their caregivers.

Accept help when it is offered: Many caregivers refuse help when it is first offered, often because of a belief that they "should" be able to manage alone, or because accepting help feels like an admission that the situation is serious. Accepting help early, before you need it desperately, is much better for everyone. Specific tasks that can be delegated to helpers: grocery shopping, transportation to appointments, meal preparation, companionship/socialization visits, yard work, or financial bill-paying.

Connect with others who understand: Online and in-person support groups for Lewy Body Dementia (LBDA support group locator at lbda.org) provide a community that understands the specific challenges of PDD — the hallucinations, the fluctuations, the antipsychotic sensitivity, the motor-cognitive dual burden — in a way that generic dementia support groups do not. Many caregivers report that connecting with a community that has the same experience is one of the most powerful supports they find.

Set achievable goals, not perfect ones: PDD will progress. The goal of care is not to stop progression or to deliver perfect care — it is to provide the best quality of life possible for the person with PDD, and to preserve the caregiver's own health and wellbeing enough to continue providing that care. Days when you did not do everything perfectly are not failures; they are normal. What matters is the sustained quality of presence and care over months and years, not perfection on any individual day.

Use your own healthcare team: Caregiver depression is common and treatable. If your primary care physician does not know you are the primary caregiver for someone with PDD, tell them — it is clinically relevant to your own health. Ask about caregiver-specific mental health resources, including brief counseling or medication for depression or anxiety if needed.

Support groups serve two populations with different needs: the person living with PDD (especially in earlier stages), and caregivers and family members. Research shows that participation in support groups is associated with lower caregiver burden scores, better problem-solving ability, and reduced isolation. What to expect from different types of groups:

• Parkinson’s disease support groups (general): Address motor and non-motor PD symptoms broadly. Useful especially in early PDD. People in earlier stages often connect with others who are managing similar challenges. Find through Parkinson’s Foundation (parkinson.org/find-support) or American Parkinson Disease Association (apdaparkinson.org).
• Dementia caregiver support groups: Address cognitive and behavioral challenges that Parkinson’s-specific groups may not fully address. Alzheimer’s Association (alz.org/care/support-groups) offers hundreds of in-person and virtual groups nationally.
• Lewy body dementia-specific support groups: Directly address PDD and DLB. The Lewy Body Dementia Association (LBDA; lbda.org) offers a peer support line (1-800-539-9767) and an LBD Caregiver Link matching program connecting caregivers with trained volunteer mentors who have direct LBD caregiving experience.
• Online and virtual groups: Many families find virtual groups more accessible once mobility or transportation becomes challenging. Facebook groups for Lewy Body Dementia Caregiver Support and similar communities have large active memberships. Quality varies; prioritize groups moderated by recognized advocacy organizations.
• Young-onset PDD groups: For people diagnosed with PD before age 50 who develop PDD, or for younger caregivers, separate peer groups address the distinctive challenges (employment, parenting, financial impact on younger families).

Respite care provides temporary relief for the primary caregiver — ranging from a few hours to several weeks. Chronic caregiver fatigue without respite is associated with depression, physical health decline, and premature placement of the person with PDD in a care facility. Types of respite:

• In-home respite (companion aide): A paid aide stays with the person while the caregiver is away. Access through home care agencies (check with insurance; Medicaid waiver programs often fund these). In Utah, the Adult Day Services program and Area Agency on Aging (1-877-424-4640) can connect families with in-home respite providers.
• Adult day health programs: The person with PDD attends a structured program several days a week in a supervised setting, providing cognitive stimulation, socialization, and medical oversight while the caregiver works or rests. These programs often have exceptional staff trained in dementia care. Ask the neurologist or social worker for referrals in your area.
• Short-stay (overnight) respite: Some skilled nursing facilities and residential care facilities offer short-term respite admissions (typically 1–2 weeks) for planned caregiver vacations, caregiver illness, or family emergencies. Medicaid may fund short-stay respite; check with the care facility directly about eligibility and waitlists.
• Family and friend respite: Many caregivers underutilize their social network because they feel others "wouldn’t know what to do." Training family members and trusted friends in basic care routines — with the help of a home health aide who can demonstrate — expands the available respite pool significantly.

Legal planning is one of the most important early steps after a PDD diagnosis. The goal is to ensure that the person's wishes are documented while they still have the cognitive capacity to legally execute documents. Waiting too long risks losing the ability to plan independently.

Priority documents (execute within the first 6–12 months of diagnosis):

• Durable Power of Attorney (DPOA) for finances: Designates a trusted person to manage financial affairs when the person with PDD can no longer do so. This is different from a standard power of attorney, which becomes invalid if the person becomes incapacitated. A durable POA remains in effect even after incapacity.
• Healthcare Power of Attorney / Healthcare Proxy: Designates a person to make medical decisions if the person with PDD cannot. This person should understand the person's values and wishes, and should be someone who can make difficult decisions under pressure.
• Living Will / Advance Directive: Documents the person's wishes about life-sustaining treatment (CPR, mechanical ventilation, feeding tubes, IV fluids) in specific scenarios. Utah uses a form called the Advance Health Care Directive. Your neurologist or hospital social worker can provide the form.
• POLST (Physician Orders for Life-Sustaining Treatment): A medical order (not just a directive) that translates the person's wishes into specific, actionable instructions for emergency medical personnel. This is especially important as PDD progresses, because EMTs and emergency physicians who do not know the patient will default to aggressive resuscitation without a POLST. In Utah, this is called a POLST form and must be signed by a physician.
• Will and trust review: Review existing wills and trusts with an elder law attorney to ensure they still reflect the person's wishes and are structured appropriately for a family navigating a progressive illness.

Most families want to care for someone with PDD at home for as long as possible. Planning for the stages in advance allows better decision-making when the time comes, rather than crisis-driven placement decisions.

Early-to-moderate PDD (typically years 1–4 of dementia): Most people can remain at home with a caregiver (spouse, adult child, or combination). Home safety modifications (grab bars, stair rails, removing trip hazards, nightlights, door alarms) significantly reduce fall and wandering risk. Adult day programs provide structured socialization and cognitive stimulation while giving caregivers a break. Home health aides can assist with bathing, medication management, and transportation.

Moderate PDD (typically years 3–6 of dementia): Full-time care at home becomes a major undertaking. For families without a full-time caregiver, memory care residential facilities or assisted living with memory care units may be appropriate. When evaluating facilities, ask specifically about their experience with Parkinson's disease dementia and Lewy body dementia — as distinct from Alzheimer's disease — because the behavioral profile (hallucinations, severe motor disability, falls) is substantially different.

Advanced PDD: People in advanced PDD are often immobile and fully dependent for all activities of daily living, with significant swallowing difficulty. Skilled nursing facilities or hospice at home are typically the appropriate settings. The key decisions at this stage are around the goals of care: pursuing hospitalizations and resuscitation vs. prioritizing comfort and quality of remaining time.

• Medicare Part D (prescription drug coverage): Covers most medications used in PDD (rivastigmine, memantine, pimavanserin). Extra Help / Low Income Subsidy (LIS) program reduces Part D costs for low-income beneficiaries. Apply through Social Security Administration at ssa.gov.
• Medicaid Waiver Programs (Utah): Utah's DSPD (Division of Services for People with Disabilities) and DAAS (Division of Aging and Adult Services) offer home and community-based waiver programs that pay for home health aides, adult day programs, and respite care for low-income individuals. Waitlists exist; apply early.
• Veterans benefits: Veterans with PDD may qualify for Aid & Attendance (a pension supplement for veterans who need help with daily activities), the Caregiver Support Program, and community-based care programs through the VA. The VA Wahlen Medical Center in Salt Lake City has a geriatrics and extended care service that handles these applications.
• Social Security Disability Insurance (SSDI): If the person with PDD is under 65 and is unable to work due to PDD and Parkinson's, they may qualify for SSDI. Parkinson's disease with dementia may qualify for expedited processing under the SSA Compassionate Allowances list.
• Pharmaceutical patient assistance programs: Acadia Pharmaceuticals (maker of Nuplazid/pimavanserin), Novartis (Exelon/rivastigmine), and Forest Labs (Namenda/memantine) all have patient assistance programs for people who cannot afford medications. Ask your neurologist's office for assistance with enrollment, or contact the manufacturer directly.

Most people have heard of new Alzheimer’s treatments such as lecanemab (Leqembi) and donanemab, which remove amyloid plaques from the brain. These drugs have shown benefit in early Alzheimer’s disease. However, they do not work in PDD or DLB because the primary pathology in PDD is alpha-synuclein (Lewy bodies), not amyloid. While some people with PDD also have co-occurring amyloid, removing amyloid alone does not address the Lewy body component. These drugs have not been studied in PDD and are not currently indicated for it.

Similarly, anti-tau therapies being developed for Alzheimer’s disease are unlikely to be the right target for PDD, which has a different primary molecular pathology. Families who read about Alzheimer’s advances should understand that those trials typically explicitly excluded Lewy body disease.

Several medication classes that are standard treatments for behavioral symptoms in other dementias (Alzheimer’s, vascular dementia) are specifically dangerous in PDD due to Lewy body neuroleptic sensitivity. This has caused real harm historically, when the Lewy body nature of PDD was not yet widely recognized.

• Typical antipsychotics (haloperidol, perphenazine): Can cause sudden, severe, life-threatening reactions in Lewy body disease including rigidity, respiratory failure, and neuroleptic malignant syndrome-like states. These should never be used in PDD.
• Most atypical antipsychotics (risperidone, olanzapine): Even lower-risk atypical antipsychotics used in Alzheimer’s disease carry significant risks in PDD. Motor worsening, excessive sedation, and paradoxical worsening of psychosis have all been reported.
• Metoclopramide (Reglan) for nausea: A dopamine blocker commonly given for nausea or gastroparesis. Causes acute and sometimes irreversible motor worsening in PD and PDD. Safer antiemetic alternatives exist (ondansetron, domperidone where available).
• Benzodiazepines for sleep or agitation: While they are sedating, benzodiazepines paradoxically worsen cognition and increase fall risk in PDD without consistently improving behavior. They also suppress REM sleep (already often disrupted in PDD). Short-term use in specific situations may be acceptable; long-term use for behavioral management is not recommended.

Many families explore supplements and complementary approaches for PDD. While some carry low risk, none has been proven to slow or halt PDD progression in clinical trials. The most common ones families ask about:

• Omega-3 fatty acids (fish oil): Theoretically anti-inflammatory; no RCT evidence for benefit in PDD cognitive decline specifically. Safe at standard doses. Not a substitute for other proven strategies.
• Coconut oil / MCT oil: Widely promoted online as a dementia treatment based on a single anecdotal case report (not a clinical trial). No controlled trial evidence in PDD or any other dementia type.
• High-dose vitamin E: Studied in Alzheimer’s disease (negative result). Not studied adequately in PDD and high-dose vitamin E carries cardiovascular risk at doses >400 IU/day.
• Herbal supplements: Many interact with PDD medications. Ginkgo biloba interacts with anticoagulants and has produced inconsistent results in dementia trials. St. John’s Wort is a strong drug interaction risk (CYP3A4 inducer) that can reduce levels of many medications used in PDD. Always disclose supplements to the neurology team.